The role of polyclonal intravenous immunoglobulin in treating HIV-infected children with severe bacterial infections: A retrospective cohort study
2008

IVIG Treatment for HIV-Infected Children with Infections

Sample size: 140 publication Evidence: moderate

Author Information

Author(s): Lyen C Huang, Landon Myer, Heather B Jaspan

Primary Institution: University of Cape Town

Hypothesis

Does intravenous immunoglobulin (IVIG) reduce mortality and length of hospital stay in HIV-infected children with serious bacterial infections?

Conclusion

IVIG does not appear to reduce mortality or hospital stays in HIV-infected children with serious bacterial infections.

Supporting Evidence

  • 73 (52%) of children were treated with IVIG.
  • 13 (9%) died during their hospital admission.
  • IVIG was associated with longer hospital stays.

Takeaway

Giving IVIG to sick children with HIV and infections didn't help them get better or leave the hospital faster.

Methodology

Retrospective cohort study of pediatric admissions with confirmed HIV and serious bacterial infections from 2002 to 2006.

Potential Biases

Confounding by indication due to treatment assignment based on illness severity.

Limitations

Retrospective design may lead to confounding by indication; severity of illness may not have been adequately captured.

Participant Demographics

Median age 1.2 years, 54% male, 39% on antiretroviral therapy, 28% on tuberculosis treatment.

Statistical Information

P-Value

0.123

Confidence Interval

95% CI: 1.2–27.1

Statistical Significance

p = 0.123

Digital Object Identifier (DOI)

10.1186/1471-2334-8-127

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication